This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
GSK Gets EU Approval for Expanded Use of Nucala in COPD
by Zacks Equity Research
GSK secures EU approval for Nucala, an add-on maintenance treatment for chronic obstructive pulmonary disease in adults.
GSKPositive Net Change ALKSPositive Net Change CSTLPositive Net Change IMCRPositive Net Change
biotechs
KOD Stock Up 24% in 3 Months: Here's What You Need to Know
by Zacks Equity Research
Kodiak Sciences' shares jump 24% in three months as late-stage retinal programs advance and fresh funding extends its cash runway, fueling investor confidence.
ALKSPositive Net Change ASRTPositive Net Change KODPositive Net Change CSTLPositive Net Change
biotechs
BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View
by Zacks Equity Research
Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.
BIIBPositive Net Change RHHBYPositive Net Change SUPNPositive Net Change
biotechs earnings medical pharmaceuticals
Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study
by Zacks Equity Research
Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.
JNJPositive Net Change BAYRYNegative Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO, LLY Stocks Slide as HIMS Launches $49 Compounded Semaglutide Pill
by Ekta Bagri
HIMS shakes up the weight loss market with a $49 compounded semaglutide pill, pressuring Novo Nordisk and Eli Lilly shares and sparking FDA and legal pushback.
NVOPositive Net Change LLYPositive Net Change HIMSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY heads into Q4 earnings with strong Jakafi sales, rising royalties and multiple new launches contributing to revenues, setting the stage for a potential upside surprise.
NVSPositive Net Change LLYPositive Net Change INCYPositive Net Change MRNAPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
by Zacks Equity Research
VSTM shares rise nearly 8% after the release of preliminary fourth-quarter 2025 and full-year 2025 sales numbers, driven by Avmapki Fakzynja Co-pack.
ALKSPositive Net Change VSTMPositive Net Change ASRTPositive Net Change CSTLPositive Net Change
biotechs
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs.
BMYPositive Net Change PFEPositive Net Change ALKSPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
NBIX heads into fourth-quarter earnings with Ingrezza sales strength, growing Crenessity revenues and rising focus on late-stage pipeline updates.
MRNAPositive Net Change NBIXPositive Net Change CRSPPositive Net Change CSTLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?
by Zacks Equity Research
GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals